March 1 (Reuters) - Mydecine Innovations Group Inc MYCO.CD :* MYDECINE FULLY COMPLETES FIRST-EVER INTERNATIONAL EXPORT OF PSILOCYBIN MUSHROOMS AND SOLIDIFIES ITS CLINICAL AND...
Feb 3 (Reuters) - Mydecine Innovations Group Inc MYCO.CD :* MYDECINE INNOVATIONS GROUP APPOINTS JOSEPHINE WU TO BOARD OF DIRECTORS
Jan 27 (Reuters) - Mydecine Innovations Group Inc MYCO.CD :* MYDECINE INNOVATIONS GROUP FILES APPLICATION TO LIST TO THE NASDAQ
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
| Technical Indicators | Sell | Strong Buy | Strong Sell | Strong Sell | Strong Sell |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 191.89 | 191.96 | 188.54 | +2.67 | +1.41% | 39.48K | Toronto | |||
| 6.16 | 6.41 | 6.10 | -0.12 | -1.91% | 4.81M | Toronto | |||
| 10.34 | 10.44 | 9.80 | +0.460 | +4.66% | 1.05M | Toronto | |||
| 2,223.53 | 2,229.25 | 2,156.21 | +58.36 | +2.70% | 31.25K | Toronto | |||
| 1.40 | 1.42 | 1.38 | -0.020 | -1.41% | 194.42K | Toronto | |||
| 0.04 | 0.00 | 0.00 | 0.000 | 0.00% | 894.36K | NEO | |||
| 184.72 | 185.14 | 182.51 | +0.80 | +0.43% | 248.56K | Toronto | |||
| 0.16 | 0.00 | 0.00 | +0.0100 | +6.67% | 183.05K | TSXV | |||
| 30.99 | 31.00 | 30.99 | 0.00 | 0.00% | 0.00 | Toronto | |||
| 14.25 | 14.64 | 14.11 | -0.18 | -1.25% | 5.98M | Toronto | |||
| 23.25 | 23.49 | 23.06 | +0.18 | +0.78% | 2.39M | Toronto | |||
| 26.86 | 26.86 | 26.86 | -0.14 | -0.52% | 200.00 | Toronto | |||
| 0.01 | 0.00 | 0.00 | 0.000 | 0.00% | 0.00 | TSXV | |||
| 57.54 | 57.75 | 56.59 | +0.43 | +0.75% | 441.04K | Toronto | |||
| 62.19 | 62.33 | 61.25 | +0.22 | +0.36% | 416.31K | Toronto |
Mydecine Innovations Group Inc., a biotech and life sciences company, engages in the development and commercialization of drugs for treating mental health problems. It develops therapies for veterans, emergency medical service providers, post-traumatic stress disorder, and frontline workers, as well as provides digital health platform and therapeutics; and mental health solutions. The company also engages in the drug discovery and builds nature-sourced psychedelic-assisted therapeutics, compounds, therapy protocols, and unique delivery systems. In addition, it operates farm properties in North America. Mydecine Innovations Group Inc. has a partnership with Applied Pharmaceutical Innovation for drug development and clinical trial programs. The company was formerly known as NewLeaf Brands Inc. and changed its name to Mydecine Innovations Group Inc. in June 2020. Mydecine Innovations Group Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.